<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>De novo</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Icecure gets FDA nod for Prosense cryoablation in breast cancer</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[Icecure Medical Ltd. reported that the U.S. FDA has granted marketing authorization to Icecure's de novo application for the Prosense cryoablation system for the local treatment of breast cancer in patients 70 years of age or older with biologically low-risk tumors. The authorized indication includes patients that are not suitable for surgery for breast cancer treatment.  ]]>
      </description>
      <guid>http://www.bioworld.com/articles/724792</guid>
      <pubDate>Mon, 06 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724792-icecure-gets-fda-nod-for-prosense-cryoablation-in-breast-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/8-11-Icecure.webp?t=1759782827" type="image/png" medium="image" fileSize="639931">
        <media:title type="plain">Illustration of cryoblation procedure in breast</media:title>
        <media:description type="plain">The Icecure Prosense system creates an iceball at breast tumor site. Credit: Icecure Medical Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA posts another batch of regulations for de novo devices</title>
      <description>
        <![CDATA[The U.S. FDA released another series of regulations for de novo devices, but the attendant regulation is not always available for these de novo devices.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723183</guid>
      <pubDate>Wed, 20 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723183-fda-posts-another-batch-of-regulations-for-de-novo-devices</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Gears-with-words.webp?t=1701979068" type="image/jpeg" medium="image" fileSize="381498">
        <media:title type="plain">Gears with regulatory words</media:title>
      </media:content>
    </item>
    <item>
      <title>Tissium’s polymer solution set to transform nerve repair after FDA nod</title>
      <description>
        <![CDATA[Could the U.S. FDA’s de novo marketing authorization for Tissium SA’s Coaptium Connect, an atraumatic sutureless solution for peripheral nerve repair, signal a transformative shift away from sutures in nerve surgery? Only time will tell.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721141</guid>
      <pubDate>Mon, 30 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721141-tissiums-polymer-solution-set-to-transform-nerve-repair-after-fda-nod</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/tissium-30june25.webp?t=1751320285" type="image/jpeg" medium="image" fileSize="191903">
        <media:title type="plain">tissium</media:title>
        <media:description type="plain">Tissium Coaptium Connect system. Credit: Tissium</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA releases another batch of regs for de novo decisions</title>
      <description>
        <![CDATA[It appears the U.S. FDA believes it’s never a bad time to release regulatory information about devices granted market access via the de novo program. The agency recently posted information on the vintage de novo granted in 2018 to Imagen Technologies Inc. for the company’s Osteo Detect algorithm.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721119</guid>
      <pubDate>Tue, 17 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721119-fda-releases-another-batch-of-regs-for-de-novo-decisions</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/regulatory-FDA-de-novo.webp?t=1588870576" type="image/png" medium="image" fileSize="1941977">
        <media:title type="plain">De novo key on keyboard</media:title>
      </media:content>
    </item>
    <item>
      <title>J&amp;J reports completion of first cases with Ottava robotic system</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[Johnson & Johnson’s Medtech division reported the completion of the first cases in the clinical trial for the Ottava robotic surgical system. The cases mark the first clinical experience with the Ottava system, which has been a long time in development. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/719131</guid>
      <pubDate>Tue, 15 Apr 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719131-j-and-j-reports-completion-of-first-cases-with-ottava-robotic-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/1-26--Da-Vinci-Xi-robot-Intuitive-Surgical.webp?t=1744749714" type="image/png" medium="image" fileSize="1246255">
        <media:title type="plain">Da Vinci Xi robot - Intuitive Surgical</media:title>
        <media:description type="plain">The updated Ottava will feature four arms, like competitor Da Vinci Xi robot (pictured) from Intuitive Surgical. Credit: Intuitive Surgical Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA authorizes first home flu and COVID-19 combo test outside EUA</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[The U.S. FDA granted marketing authorization for Healgen Scientific LLC’s Rapid Check COVID-19/Flu A&B antigen test.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712921</guid>
      <pubDate>Tue, 08 Oct 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712921-fda-authorizes-first-home-flu-and-covid-19-combo-test-outside-eua</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Healgen-test-8oct24.webp?t=1728421496" type="image/png" medium="image" fileSize="310638">
        <media:title type="plain">Healgen COVID-Flu OTC test kit</media:title>
        <media:description type="plain">Healgen Scientific's Rapid Check COVID-19/Flu A&amp;amp;B antigen test. Credit: Healgen Scientific LLC</media:description>
      </media:content>
    </item>
    <item>
      <title>Digital products lead FDA’s de novo parade for September</title>
      <description>
        <![CDATA[The U.S. FDA posted a series of de novo decisions Sept. 9, including a digital diagnostic for chronic kidney disease progression by Renalytix AI Inc., of New York, and a digital therapy device for management of fibromyalgia symptoms by Swing Therapeutics Inc., of San Francisco.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712017</guid>
      <pubDate>Tue, 10 Sep 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712017-digital-products-lead-fdas-de-novo-parade-for-september</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/regulatory-FDA-de-novo.webp?t=1588870576" type="image/png" medium="image" fileSize="1941977">
        <media:title type="plain">De novo key on keyboard</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA still playing catch-up on de novo device classifications</title>
      <description>
        <![CDATA[The U.S. FDA is accused of dragging its feet on making public the devices for which it granted market access under the de novo program, and the agency recently been scrambling to bring these decision summaries to light.]]>
      </description>
      <guid>http://www.bioworld.com/articles/711940</guid>
      <pubDate>Wed, 04 Sep 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/711940-fda-still-playing-catch-up-on-de-novo-device-classifications</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-approved-seal-on-blue-background.webp?t=1723739183" type="image/jpeg" medium="image" fileSize="197102">
        <media:title type="plain">FDA approval seal on blue glittering background</media:title>
      </media:content>
    </item>
    <item>
      <title>Scopio wins FDA clearance for bone marrow aspirate application</title>
      <description>
        <![CDATA[The U.S. FDA granted Scopio Labs Ltd. de novo clearance for its artificial intelligence (AI)-powered software which analyzes bone marrow. Scopio’s Full-Field Bone Marrow Aspirate (FF-BMA) system aims to improve patient care by standardizing bone marrow aspirate analysis and elevating diagnostic precision.]]>
      </description>
      <guid>http://www.bioworld.com/articles/707454</guid>
      <pubDate>Thu, 18 Apr 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/707454-scopio-wins-fda-clearance-for-bone-marrow-aspirate-application</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Bone-marrow-HERO.webp?t=1675437585" type="image/png" medium="image" fileSize="388368">
        <media:title type="plain">Bone marrow illustration with doctor background</media:title>
      </media:content>
    </item>
    <item>
      <title>Virtual Incision’s miniature robotic surgery device gets FDA nod</title>
      <description>
        <![CDATA[The U.S. FDA granted Virtual Incision Corp. de novo marketing authorization for its miniaturized in vivo robotic assistant for use in colectomy procedures in adults. The two-pound device offers portability and quick setup, eliminating the need for specialized operating rooms or arrangements to accommodate robotics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/705840</guid>
      <pubDate>Mon, 26 Feb 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705840-virtual-incisions-miniature-robotic-surgery-device-gets-fda-nod</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/MIRA-Virtual-Incision-26feb24.webp?t=1708988756" type="image/jpeg" medium="image" fileSize="60809">
        <media:title type="plain">MIRA Virtual Incision</media:title>
        <media:description type="plain">Virtual Incision Inc.’s MIRA system granted FDA de novo authorization for use in colectomy. Credit: Virtual Incision</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA blows good news Bluewind’s way with de novo approval for urgency incontinence device</title>
      <description>
        <![CDATA[The U.S. FDA granted the de novo marketing request for Bluewind Medical Ltd.’s Revi system for the treatment of urgency incontinence with or without urinary urgency, the company reported on August 17. Unlike other neuromodulation devices approved in recent years, Revi stimulates the tibial nerve instead of the sacral nerves.]]>
      </description>
      <guid>http://www.bioworld.com/articles/700077</guid>
      <pubDate>Fri, 18 Aug 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/700077-fda-blows-good-news-bluewinds-way-with-de-novo-approval-for-urgency-incontinence-device</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/Revi-cuff-18aug23.webp?t=1692394980" type="image/jpeg" medium="image" fileSize="191864">
        <media:title type="plain">Bluewind Revi cuff</media:title>
        <media:description type="plain">Revi is activated with a lightweight, wearable cuff once or twice a day. Credit: Bluewind Medical Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA grants de novo to Masimo Opioid Halo</title>
      <description>
        <![CDATA[Masimo Corp.’s Opioid Halo, an opioid overdose prevention and alert system, was granted de novo status by the U.S. FDA. The device detects opioid-induced respiratory depression, the primary cause of opioid deaths. The de novo authorizes the company to make Halo available over the counter and by prescription for use on individuals aged 15 and up.]]>
      </description>
      <guid>http://www.bioworld.com/articles/695727</guid>
      <pubDate>Mon, 03 Apr 2023 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/695727-fda-grants-de-novo-to-masimo-opioid-halo</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/04-03-Masimo-Opioid-Halo.webp?t=1680557084" type="image/png" medium="image" fileSize="418370">
        <media:title type="plain">Masimo Opioid Halo finger monitor and mobile app</media:title>
        <media:description type="plain">Masimo’s Opioid Halo system.</media:description>
      </media:content>
    </item>
    <item>
      <title>Medasense gets FDA nod for its nociception technology</title>
      <description>
        <![CDATA[Medasense Biometrics Ltd. received U.S. FDA marketing authorization for its PMD-200 patient monitor with nociception level index (NOL) technology that monitors patients’ physiological response to pain during surgery. NOL uses a multi-parametric sensor platform combined with artificial intelligence (AI) algorithms to generate a ‘signature of pain’ for patients under anesthesia who are also receiving opioids and other analgesics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/694531</guid>
      <pubDate>Thu, 23 Feb 2023 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/694531-medasense-gets-fda-nod-for-its-nociception-technology</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/Medasense-PMD-200-NOL-monitoring.webp?t=1677190866" type="image/png" medium="image" fileSize="1342478">
        <media:title type="plain">PMD 200 platform in operating room</media:title>
        <media:description type="plain">Medasense Biometrics Ltd.’s PMD-200 with nociception level index helps clinicians personalize analgesia during surgery and reduce postoperative pain.</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA playing catch-up on regulations with a fistful of de novos </title>
      <description>
        <![CDATA[Playwright George Bernard Shaw is credited with coining the phrase, “better late than never,” a piece of advice the U.S. FDA seems to have taken to heart when it comes to posting the regulations for first-of-a-kind devices. The agency has posted eight regulations for de novo devices just between Jan. 4 and Jan. 5, 2023, five of those arriving on the latter of those two days in a post-holiday scramble to catch up.]]>
      </description>
      <guid>http://www.bioworld.com/articles/693060</guid>
      <pubDate>Fri, 06 Jan 2023 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/693060-fda-playing-catch-up-on-regulations-with-a-fistful-of-de-novos</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-website-and-logo.webp?t=1632866648" type="image/png" medium="image" fileSize="443242">
        <media:title type="plain">FDA website and logo</media:title>
        <media:description type="plain">Credit: Postmodern Studio - stock.adobe.com</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA provides five more device classifications via de novo petition</title>
      <description>
        <![CDATA[The FDA’s device center has long been at the task of reclassifying legacy devices that promise a moderate degree of risk, but successful de novo device applications also call for a class II listing. The agency recently posted five such risk classifications, including for a device developed by Edwards Lifesciences Corp., of Irvine, Calif.]]>
      </description>
      <guid>http://www.bioworld.com/articles/516233</guid>
      <pubDate>Fri, 18 Feb 2022 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/516233-fda-provides-five-more-device-classifications-via-de-novo-petition</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-construction-blocks.webp?t=1620679875" type="image/png" medium="image" fileSize="1532716">
        <media:title type="plain">Toy bulldozer moving FDA letter blocks</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA announces four new class II device designations</title>
      <description>
        <![CDATA[The FDA’s device center reported the addition of four device types to the ranks of class II devices, including one each for de novo petitions by Apple Inc., of Cupertino, Calif., and Roche Molecular Systems Inc., of Pleasanton, Calif.]]>
      </description>
      <guid>http://www.bioworld.com/articles/515837</guid>
      <pubDate>Mon, 07 Feb 2022 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/515837-fda-announces-four-new-class-ii-device-designations</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-icons.webp?t=1588870105" type="image/png" medium="image" fileSize="458141">
        <media:title type="plain">FDA icons</media:title>
      </media:content>
    </item>
    <item>
      <title>Class II designation finally effective for cerebrospinal fluid shunts </title>
      <description>
        <![CDATA[Glaciers are known to move slowly, but so is government, and the FDA needed seven years to make effective an order that cerebrospinal fluid shunts be deemed class II devices. The classification was applicable as of Aug. 22, 2014, in connection with a de novo petition filed by no less than industry colossus Medtronic plc, of Dublin, in a process that began in 2012, possibly earlier.]]>
      </description>
      <guid>http://www.bioworld.com/articles/514729</guid>
      <pubDate>Fri, 31 Dec 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/514729-class-ii-designation-finally-effective-for-cerebrospinal-fluid-shunts</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-yellow-dice.webp?t=1626471222" type="image/png" medium="image" fileSize="416581">
        <media:title type="plain">Hand holding FDA blocks</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA’s pressure on 510(k) process a factor in lawsuit between J&amp;J, Auris</title>
      <description>
        <![CDATA[The FDA’s regulation of medical technology may be assumed to have a number of unintended consequences, and one of those seems to be the lawsuit between Johnson & Johnson (J&J) and Auris Health Inc. Due to a 2018 FDA policy change regarding 510(k) devices, a robotic surgery system acquired by a J&J subsidiary from Auris was forced into the lengthier de novo premarket channel. This change ultimately helped derail the development effort for the Auris Iplatform surgical system and thus played a role in the $2.35 billion lawsuit alleging that J&J had engaged in fraud in its deal with Auris over the acquisition.]]>
      </description>
      <guid>http://www.bioworld.com/articles/514356</guid>
      <pubDate>Thu, 16 Dec 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/514356-fdas-pressure-on-510k-process-a-factor-in-lawsuit-between-j-and-j-auris</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-icons.webp?t=1588870105" type="image/png" medium="image" fileSize="458141">
        <media:title type="plain">FDA icons</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA slots five device types into class II, including for de novo granted in 2011</title>
      <description>
        <![CDATA[The FDA’s device center is required to develop and publish special controls for devices that are deemed class II items via the de novo petition process, and five such declarations were posted Dec. 1 to the <em>Federal Register</em>. One of these de novo classifications, for conditioning tools for eating disorders, was the subject of a de novo petition filed in 2007 and granted in 2011.]]>
      </description>
      <guid>http://www.bioworld.com/articles/513892</guid>
      <pubDate>Wed, 01 Dec 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/513892-fda-slots-five-device-types-into-class-ii-including-for-de-novo-granted-in-2011</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-yellow-dice.webp?t=1626471222" type="image/png" medium="image" fileSize="416581">
        <media:title type="plain">Hand holding FDA blocks</media:title>
      </media:content>
    </item>
    <item>
      <title>Hemolung respiratory assist system gets de novo nod</title>
      <description>
        <![CDATA[Patients and investors in Alung Technologies Inc. can breathe a little easier now that the company’s Hemolung respiratory assist system has won a de novo approval from the FDA. The FDA approval comes more than eight years after Hemolung received CE mark and Health Canada approval. Hemolung gained FDA emergency use authorization for patients with COVID-19 in April 2020.]]>
      </description>
      <guid>http://www.bioworld.com/articles/513393</guid>
      <pubDate>Mon, 15 Nov 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/513393-hemolung-respiratory-assist-system-gets-de-novo-nod</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/11-15-Alung-Hemolung.webp?t=1637016288" type="image/png" medium="image" fileSize="447078">
        <media:title type="plain">Doctor, patient using Hemolung</media:title>
        <media:description type="plain">Hemolung respiratory assist system. Credit: Alung Technologies Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Feops Heartguide granted FDA de novo authorization for LAAo planning</title>
      <description>
        <![CDATA[Feops SA reported that its Heartguide product has received de novo authorization from the FDA for pre-operative planning of left atrial appendage occlusion (LAAo) with the Boston Scientific Corp. Watchman device. The software platform is designed to help physicians virtually model clinical scenarios with different implant positions and sizes of the Watchman device using digital twin technology based on patient-specific virtual replicas of the heart. It is currently commercially available in the EU, U.K., Canada and Australia for transcatheter aortic valve implantation and LAAo workflows.]]>
      </description>
      <guid>http://www.bioworld.com/articles/512436</guid>
      <pubDate>Fri, 15 Oct 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/512436-feops-heartguide-granted-fda-de-novo-authorization-for-laao-planning</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Heart.webp?t=1634333052" type="image/png" medium="image" fileSize="440122">
        <media:title type="plain">Digital heart illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA retains pre-inspection features in final rule for de novo petitions</title>
      <description>
        <![CDATA[The FDA’s final rule for the de novo petition process took nearly three years to wrap up, a timeline likely extended by the COVID-19 pandemic, but the final rule retains some controversial features seen in the 2018 draft. Among these is a provision for FDA inspections before determining whether to grant the petition, a provision that was blasted by multiple commenters as extra-statutory and a needless source of drag on these applications.]]>
      </description>
      <guid>http://www.bioworld.com/articles/512085</guid>
      <pubDate>Tue, 05 Oct 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/512085-fda-retains-pre-inspection-features-in-final-rule-for-de-novo-petitions</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Regulatory-US-FDA-HQ.webp?t=1707859292" type="image/png" medium="image" fileSize="2264756">
        <media:title type="plain">U.S. FDA headquarters</media:title>
      </media:content>
    </item>
    <item>
      <title>Paige receives FDA de novo authorization for AI product for prostate cancer detection</title>
      <description>
        <![CDATA[The FDA granted de novo marketing authorization for Paige Prostate, artificial intelligence (AI)-driven software that improves detection of prostate cancer. The clinical study submitted to the FDA demonstrated that using Paige Prostate resulted in a 7% improvement in sensitivity in correctly diagnosing cancer, increasing from 89.5% to 96.8%.]]>
      </description>
      <guid>http://www.bioworld.com/articles/511688</guid>
      <pubDate>Wed, 22 Sep 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/511688-paige-receives-fda-de-novo-authorization-for-ai-product-for-prostate-cancer-detection</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/09-22-Paige-System.webp?t=1632346408" type="image/png" medium="image" fileSize="421997">
        <media:title type="plain">Woman using Paige software on tablet</media:title>
        <media:description type="plain">Credit: Paige.ai Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Zimmer, Canary advance the cause of digital orthopedics with smart knee implant</title>
      <description>
        <![CDATA[Digital health has made only limited headway in the orthopedics space, but Zimmer Biome Inc. and Canary Medical Inc. have nudged the cause along with a smart implant that blends a 21st century sensor with a traditional knee replacement device. The marriage of Zimmer&rsquo;s Persona knee implant and the Canary Medical Canturio TE sensor will give physicians a better way to track the patient&rsquo;s recovery from knee replacement procedures.]]>
      </description>
      <guid>http://www.bioworld.com/articles/510913</guid>
      <pubDate>Mon, 30 Aug 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/510913-zimmer-canary-advance-the-cause-of-digital-orthopedics-with-smart-knee-implant</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-handshake-wire-frame.webp?t=1588276549" type="image/png" medium="image" fileSize="294266">
        <media:title type="plain">Gold wireframe handshake</media:title>
      </media:content>
    </item>
    <item>
      <title>De novo petitions not the same as patent protection, but some exclusivity available</title>
      <description>
        <![CDATA[Medical devices have had to deal with a large body of uncertainty where patent protection is concerned, thanks principally to jurisprudence arising out of the Supreme Court. However, Mark Mansour, a regulatory attorney with the D.C. office of Dykema Gossett PLLC, said on a recent webinar that even in the absence of a patent, de novo devices can gain some market exclusivity with smart use of labeling, a practice that can help ensure that the developer can achieve the needed return on investment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/507622</guid>
      <pubDate>Fri, 28 May 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/507622-de-novo-petitions-not-the-same-as-patent-protection-but-some-exclusivity-available</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/patent-law.webp?t=1588277944" type="image/png" medium="image" fileSize="626639">
        <media:title type="plain">Patent law book and gavel</media:title>
      </media:content>
    </item>
    <item>
      <title>Neurolutions wins de novo nod for stroke rehabilitation device</title>
      <description>
        <![CDATA[The FDA has granted de novo authorization to Neurolutions Inc. for its Ipsihand upper extremity rehabilitation system. The first-of-its kind device leverages robotics and brain-computer interface (BCI) technology to facilitate muscle training in patients with upper limb weakness or immobility following a stroke.]]>
      </description>
      <guid>http://www.bioworld.com/articles/506364</guid>
      <pubDate>Mon, 26 Apr 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/506364-neurolutions-wins-de-novo-nod-for-stroke-rehabilitation-device</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/04-26-Neurolutions-Ipsihand.webp?t=1619473718" type="image/png" medium="image" fileSize="1385731">
        <media:title type="plain">Patient wearing Ipsihand</media:title>
        <media:description type="plain">Ipsihand upper extremity rehabilitation system. Credit: Neurolutions Inc. </media:description>
      </media:content>
    </item>
    <item>
      <title>Helius gets FDA nod for first neuromodulator for MS gait issues</title>
      <description>
        <![CDATA[The FDA authorized marketing of the Portable Neuromodulation Stimulator (Pons) for short-term treatment of gait issues arising from mild to moderate symptoms associated with multiple sclerosis (MS) through its de novo pathway. Helius Medical Inc., a subsidiary of Helius Medical Technologies Inc., makes the non-implantable neuromuscular tongue stimulator.]]>
      </description>
      <guid>http://www.bioworld.com/articles/505369</guid>
      <pubDate>Tue, 30 Mar 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/505369-helius-gets-fda-nod-for-first-neuromodulator-for-ms-gait-issues</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/03-30-Helius-pons.webp?t=1617140928" type="image/png" medium="image" fileSize="516867">
        <media:title type="plain">Device components and in use</media:title>
        <media:description type="plain">Portable Neuromodulation Stimulator. Credit: Helius Medical Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Fifth Eye launches ML-based tool to predict hemodynamic instability</title>
      <description>
        <![CDATA[The FDA has granted de novo authorization to Fifth Eye Inc. for its Analytic for Hemodynamic Instability (AHI), a machine learning (ML)-based, real-time indicator of patient deterioration. Commercialization of the software device, which continuously monitors patients with an electrocardiogram (ECG) for signs of deterioration, got underway on March 1.]]>
      </description>
      <guid>http://www.bioworld.com/articles/504254</guid>
      <pubDate>Tue, 02 Mar 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/504254-fifth-eye-launches-ml-based-tool-to-predict-hemodynamic-instability</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/03-02-Fifth-Eye.webp?t=1614722821" type="image/png" medium="image" fileSize="214375">
        <media:title type="plain">Software screenshot</media:title>
        <media:description type="plain">Analytic for Hemodynamic Instability. Credit: Fifth Eye Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Study underscores effectiveness of Caption Health's AI-guided ultrasound software</title>
      <description>
        <![CDATA[Last year, artificial intelligence (AI)-focused Caption Health Inc. won the U.S. FDA&rsquo;s nod for software that guides untrained clinicians step-by-step in providing a cardiac ultrasound exam, a process normally performed by a highly skilled specialist. Now, the Brisbane, Calif.-based company has published data showing nurses without prior ultrasound experience who used Caption Guidance software captured ultrasound images of diagnostic quality to assess known cardiac conditions.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503838</guid>
      <pubDate>Fri, 19 Feb 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503838-study-underscores-effectiveness-of-caption-healths-ai-guided-ultrasound-software</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/02-19-Caption-Health-software.webp?t=1613770499" type="image/png" medium="image" fileSize="360307">
        <media:title type="plain">Product image</media:title>
        <media:description type="plain">Caption Guidance. Credit: Caption Health Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA gives nod to first-ever daytime treatment for sleep apnea</title>
      <description>
        <![CDATA[The U.S. FDA granted de novo authorization for Signifier Medical Technologies LLC&rsquo;s ExciteOSA, the first treatment for mild obstructive sleep apnea and snoring designed for daytime use. Used for 20 minutes a day, the device improves the function of the tongue muscle to prevent airway obstruction while sleeping. ExciteOSA, previously called Snoozeal, already has a CE mark.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503355</guid>
      <pubDate>Mon, 08 Feb 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503355-fda-gives-nod-to-first-ever-daytime-treatment-for-sleep-apnea</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/02-08-Signifier-ExciteOSA.webp?t=1612823804" type="image/png" medium="image" fileSize="264166">
        <media:title type="plain">Mobile app and device</media:title>
        <media:description type="plain">ExciteOSA offers first daytime treatment of obstructive sleep apnea. Credit: Signifier Medical Technologies LLC.</media:description>
      </media:content>
    </item>
  </channel>
</rss>
